KYVIVY

Live / Allowed — Fourth extension granted (statement of use) (as of 30 Apr 2026)

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 27 Sept 2023 filing date already counts against anyone who files later.

Record

Serial number
98199140
Mark type
Word mark
Filed
27 Sept 2023
Published for opposition
02 Apr 2024
Attorney of record
Scott D. Woldow

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of blood conditions; Pharmaceutical preparations for the treatment of transplant diseases, illnesses, and conditions; Pharmaceutical preparations for renal transplant diseases, illnesses, and conditions; Pharmaceutical preparations for kidney diseases, illnesses and conditions; Pharmaceutical preparations for treatment of antibody mediated rejection in adult renal transplant recipients; pharmaceutical preparations to treat hematology diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of emphysema diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, acute respiratory distress syndrome, ARDS; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations for the treatment of respiratory diseases, illnesses and conditions, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions, namely, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations for the treatment of lung diseases, illnesses and conditions, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD

Owner

Prosecution history

  • 04 Nov 2026 — SOU TEAS EXTENSION RECEIVED
  • 01 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 30 Apr 2026 — SOU EXTENSION 4 GRANTED
  • 30 Apr 2026 — SOU EXTENSION 4 FILED
  • 30 Apr 2026 — SOU TEAS EXTENSION RECEIVED
  • 05 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 04 Nov 2025 — SOU EXTENSION 3 GRANTED
  • 04 Nov 2025 — SOU EXTENSION 3 FILED
  • 04 Nov 2025 — SOU TEAS EXTENSION RECEIVED
  • 05 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 05 May 2025 — SOU EXTENSION 2 GRANTED
  • 05 May 2025 — SOU EXTENSION 2 FILED
  • 05 May 2025 — SOU TEAS EXTENSION RECEIVED
  • 04 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 04 Nov 2024 — SOU EXTENSION 1 GRANTED

View this trademark record on Rightsy